Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)
Prospective Study for the Evaluation of the Prognostic Value of NETosis Markers to Predict Thrombosis in Myeloproliferative Neoplasms With JAK2V617F Mutation (AVATARE)
University Hospital, Bordeaux
300 participants
Dec 9, 2025
INTERVENTIONAL
Conditions
Summary
Myeloproliferative neoplasms are hematologic diseases characterized by an increased proliferation of peripheral blood cells. The main risk of MPN is the occurrence of thrombosis. Thrombosis risk is mainly evaluated using two criteria: age and prior thrombosis. A better prediction of thrombosis risk is needed to improve prevention and treatment of MPN-associated thrombosis. The objective of the study is to evaluate the predictive value of neutrophil extracellular traps markers in thrombosis during MPN.
Eligibility
Inclusion Criteria7
- Diagnosis of Polycythemia Vera (PV), Essential Thrombocythemia (ET), or pre-myelofibrosis (pre-MF)
- JAK2V617F mutation with an allelic burden greater than 1%
- High risk of thrombosis (age over 60 years or prior thrombotic event)
- Diagnosis of MPN within the last 12 months
- Enrollment in the AVAJAK clinical trial and the FIMBANK biobank
- Affiliation with social security
- Signed informed consent
Exclusion Criteria3
- Severe hepatic or renal insufficiency (Creatinine clearance <30ml/min)
- Patients under legal protection (guardianship or curatorship)
- Patients under heparin treatment at inclusion
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
At inclusion (T0) and at 12 months (T1), venous blood will be drawn for plasma markers of NETosis
Locations(15)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07119970